Benzimidazole Derivatives Bearing Substituted Biphenyls as Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitors: Structure−Activity Relationship Studies and Identification of a Potent and Highly Selective Inhibitor JTK-109
Citations Over TimeTop 10% of 2006 papers
Abstract
Following the discovery of a new series of benzimidazole derivatives bearing a diarylmethyl group as inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase (HCV NS5B RdRp),1,2 we extended the structure-activity relationship (SAR) study to analogues bearing a substituted biphenyl group and succeeded in a significant advancement of activity. Starting from compound 1, optimization of the A, B, and C rings afforded potent inhibitors with low nanomolar potency against genotype 1b NS5B. The compounds, which have a substituent with a carbonyl function at the 4-position of the B-ring, efficiently blocked subgenomic viral RNA replication in the replicon cell assay at low submicromolar concentrations. Among the new compounds, compound 10n (JTK-109) exhibited favorable pharmacokinetic profiles, high selectivity for NS5B, and good safety profiles, suggesting the potential for a clinical candidate in the treatment of hepatitis C.
Related Papers
- → Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro(2003)85 cited
- → Replication Studies Using Genotype 1a Subgenomic Hepatitis C Virus Replicons(2003)67 cited
- → Persistent replication of the GBV-C subgenomic replicons in Huh7 cells(2009)3 cited
- Establishment of a cell model supporting HCV 1b subgenomic replication(2009)
- Construction of a chimeric hepatitis C virus replicon based on a strain isolated from a chronic hepatitis C patient(2014)